News & Publications

IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies

IMU Biosciences joins NVIDIA Inception Programme to Accelerate AI-Driven Precision Medicine

IMU Biosciences expands leadership team with appointment of industry experts Dr. John Baker as Chief Executive Officer and Dr. Jason Brown as Chief Business Officer

IP10 levels refine severity prognostication in COVID-19 and implicate causes of clinical deterioration: lessons for pandemic preparedness

IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine

A dynamic COVID-19 immune signature includes associations with poor prognosis